Newsroom
Sorted by: Latest
-
U.S. Physical Therapy, Inc. Schedules Fourth Quarter and Year Ended December 31, 2025 Earnings Release and Conference Call Dates
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Wednesday, February 25, 2026, after the stock market closes, with the conference call to follow the next morning, on Thursday, February 26, 2026. Conference Call Date:...
-
SmartCentres Real Estate Investment Trust Releases Fourth Quarter and Full Year Results for 2025
TORONTO--(BUSINESS WIRE)--SmartCentres Real Estate Investment Trust (“SmartCentres”, the “Trust” or the “REIT”) (TSX: SRU.UN) is pleased to report its financial and operating results for the three months and year ended December 31, 2025. “Reflecting on our 2025 results, I am pleased with our strong financial and operational performance," said Mitchell Goldhar, CEO of SmartCentres. "Our net operating income has shown steady and consistent growth through the year fueled by strong leasing momentum...
-
KD Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 13, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyndryl Holdings, Inc.
RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities fraud class action lawsuit has been filed against Kyndryl Holdings, Inc. (Kyndryl) (NYSE: KD) on behalf of those who purchased or acquired Kyndryl securities between August 7, 2024, and February 9, 2026, inclusive. The lawsuit is filed in the United States District Court for the Eastern District of New York and is captioned Brander v. Kyndryl Holdings, Inc., et al, Case No. 1:...
-
California Appeals Court Upholds $51 Million Ruling Against Avon in Mesothelioma Case
LOS ANGELES--(BUSINESS WIRE)--The California 2nd District Court of Appeals has affirmed a $51 million verdict against Avon for causing the death of a California woman who developed the terminal cancer mesothelioma after years of exposure to asbestos contained in the multinational cosmetics company’s products. Plaintiff Rita-Ann Chapman passed away in March 2025, a little more than two years after the verdict against Avon was handed down. “Companies cannot ignore science, disregard their own int...
-
Bezkonkurenční v oblasti obchodní excelence: společnosti Mary Kay se umístila na 2. místě v žebříčku Forbes 2026 Best Customer Service List (Nejlepší zákaznický servis roku 2026 podle Forbes)
DALLAS--(BUSINESS WIRE)--Společnost Mary Kay Inc., globální lídr v oblasti přímého prodeje inovativních produktů pro krásu a péči o pleť, vstoupila do roku 2026 s velkým elánem a zajistila si prestižní ocenění v žebříčku Forbes 2026 Best Customer Service, kde se společnost umístila na 2. místě. Toto ocenění navazuje na výjimečný rok pro společnost Mary Kay, která rok 2025 uzavřela s celkem 25 globálními oceněními, což podtrhuje její trvalý důraz na firemní excelence, přímý prodej, sociální dopa...
-
INVESTOR ALERT: Securities Class Action Filed Against uniQURE N.V. – Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired uniQURE N.V. (“uniQURE” or the “Company”) (NASDAQ:QURE) securities during the period of September 24, 2025 through October 31, 2025, inclusive (“the Class Period”). If you suffered a loss on your uniQURE investments, you have until April 13, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted...
-
KDDI CORPORATION INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against KDDI Corporation (“KDDI” or the “Company”) (OTC:KDDIY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 6, 2026, KDDI posted an announcement on its website entitled “Notice Regarding Expectation that...
-
CORRECTING and REPLACING Xperi to Release Fourth Quarter and Full Year 2025 Results on February 25, 2026
SAN JOSE, Calif.--(BUSINESS WIRE)--Headline of release should read: Xperi to Release Fourth Quarter and Full Year 2025 Results on February 25, 2026 The updated release reads: XPERI TO RELEASE FOURTH QUARTER AND FULL YEAR 2025 RESULTS ON FEBRUARY 25, 2026 Xperi Inc. (NYSE: XPER) (the “Company” or “Xperi”), an entertainment technology company that invents, develops, and delivers technologies that enable extraordinary experiences, will announce its Fourth Quarter and Full Year 2025 financial resul...
-
Brazos Midstream Announces Expansion of Credit Facility to $1.1 Billion
FORT WORTH, Texas--(BUSINESS WIRE)--Brazos Midstream (“Brazos”) today announced that its subsidiary, Brazos Midland, LLC, has completed an expansion of its senior credit facility to $1.1 billion from $225 million in commitments from a syndicate of banks. These funds support the ongoing expansion of Brazos’ natural gas gathering and processing system throughout the Midland Basin, one of the most robust and active oil and gas producing regions in the United States. Management Perspective “In a ma...
-
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel. “In the Phase 3 PANOVA-3 trial, treatment with Optune Pax resulted in a statistically significant improvement in overall survival without adding to the systemic side effects commonly associated with existing therapies. It also s...